Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

142.74 +2.80 (+2.00%)
Streaming Delayed Price Updated: 12:17 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
54 55 Next >
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
A Closer Look at 21 Analyst Recommendations For Biogen
 
Via Benzinga
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Biogen Unusual Options Activity
 
Via Benzinga
Peering Into Biogen's Recent Short Interest
 
Via Benzinga
Breaking Down Biogen: 8 Analysts Share Their Views
 
Via Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Getting its Alzheimer's medicine approved in the European Union could be big. 
Via The Motley Fool
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit
The company missed both sales and earnings expectations for the fourth quarter. 
Via Investor's Business Daily
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
From Biogen Inc.
Via GlobeNewswire
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
Looking At Biogen's Recent Unusual Options Activity
 
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
 
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential. 
Via InvestorPlace
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties. 
Via Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. 
Via Benzinga
Topics Economy Stocks
Why Is Biogen Stock Trading Lower On Tuesday?
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs. 
Via Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said. 
Via Benzinga
Topics Economy Stocks
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks. 
Via InvestorPlace
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.